INJECTABLE INFLUENZA VACCINE CONSENT FORM (WRITTEN)

Last Name:	F	First Name:		Date of Birth (YYYY/MM/DD):	
Address:			Telephone Numbe	 er:	
Emergency Contact and Relation:			Emergency Telephone Number:		
Personal Health Number:	Sex:	☐ Male ☐ Transgender		Pregnancy Status: □ No □ Yes □ N/A	
2 OTHER HEALTH INFO	L				
		medication If checked pleas	se snecify:		
				······································	
I have fainted during/after red			· · · _		
I am receiving a CTLA-4 inhibi	cor (e.g. ipilimumab) alor	ne or in combination with otl	ner checkpoint inhibitors f	or the treatment of cancer. *	
3 CONSENT □ (Client □ Pare	nt 🔲 Legal guardi	an 🗌 Represe	ntative	
 ☐ I consent to receiving/for my cl ☐ I will stay in the pharmacy for a ☐ I will report any adverse effects ☐ I understand the information m summary statistical information Name (PRINT)	t least 15 minutes after to a lexperience to the immonay be used and disclosed in may be reported to the	the injection and seek medic nunizing pharmacist. d in accordance with the <i>Fre</i> e Ministry of Health.	edom of Information and i	Protection of Privacy Act and that	
Signature		Date s	Date signed (YYYY/MM/DD)		
<u> </u>		FOR PHARMACIST USE O	NLY		
A VACCINE INFORMATION Name of vaccine: Dose: mL Site:	DIN: _		Ph	Pharmacy Label	
Lot #:				,	
Expiry date (YYYY/MM/DD): LA left arm; RA right arm; IM intramuscular					
5 PHARMACY INFORM	ATION				
Pharmacist signature: Licence number		er:			
Date of administration (YYYY/MM,	/DD):	Time of ac	dministration:		
6 CLIENT RESPONSE Before: Normal Yes □ No □]	15-30 mins post-adminis	tration: Normal Yes	No □	
During: Normal Yes ☐ No ☐	1	Other comments:			

^{*}Inactivated influenza vaccine should be given 8 weeks before starting treatment or 8 weeks after the last CTLA-4 inhibitor dose. For more specific details refer to the <u>BC Cancer Influenza vaccine recommendations</u>.